Quark Publishes Data Linking Proprietary Target to Pulmonary Injury, Emphysema | GenomeWeb

Quark Pharmaceuticals announced today the publication of data showing that one of its proprietary gene targets, RTP801, plays a role in cigarette smoke-induced pulmonary injury and emphysema.

In a paper published in Nature Medicine, researchers reported "increased levels of RTP801 mRNA and protein in the lungs of humans suffering from emphysema and in the lungs of mice exposed to cigarette smoke," Quark said. "Unlike normal mice, mice that could not express RTP801 did not develop emphysema following six months of intensive exposure to cigarette smoke."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.